Cargando…
Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Background: Shufeng Jiedu (SFJD) capsules can be used as adjunctive treatment for patients with community-acquired pneumonia, but the effectiveness and safety of SFJD are not clear. This review aims to evaluate the effectiveness and safety of SFJD based on randomized controlled trials (RCTs). Method...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289368/ https://www.ncbi.nlm.nih.gov/pubmed/35860018 http://dx.doi.org/10.3389/fphar.2022.923395 |
_version_ | 1784748649978265600 |
---|---|
author | Zhang, Xiao-Wen Xia, Ru-Yu Gao, Jia-Qi Liu, Jin-Jun Xu, De-Hao Li, Xun Hu, Xiao-Yang Willcox, Merlin Moore, Michael Dai, Meng-Yuan Trill, Jeanne Fei, Yu-Tong Liu, Jian-Ping |
author_facet | Zhang, Xiao-Wen Xia, Ru-Yu Gao, Jia-Qi Liu, Jin-Jun Xu, De-Hao Li, Xun Hu, Xiao-Yang Willcox, Merlin Moore, Michael Dai, Meng-Yuan Trill, Jeanne Fei, Yu-Tong Liu, Jian-Ping |
author_sort | Zhang, Xiao-Wen |
collection | PubMed |
description | Background: Shufeng Jiedu (SFJD) capsules can be used as adjunctive treatment for patients with community-acquired pneumonia, but the effectiveness and safety of SFJD are not clear. This review aims to evaluate the effectiveness and safety of SFJD based on randomized controlled trials (RCTs). Methods: A systematic review was conducted by searching PubMed, Embase, Scopus, Web of Science, CENTRAL, CNKI, VIP, CBM, Wanfang and trial registry platforms from their inception to March 2022. Two reviewers screened studies, extracted the data and assessed risk of bias independently. The data were pooled for meta-analysis or presented narratively. Results: Seventeen RCTs involving 1840 participants were included. All trials compared SFJD plus antibiotics to antibiotics, or combined with symptomatic treatment in both groups. The overall certainty of evidence was assessed as moderate to very low certainty. Compared with routine treatment (antibiotics alone or antibiotics plus symptomatic treatment), SFJD plus routine treatment showed beneficial effects in resolution of fever (MD −1.20 days, 95%CI −1.73 to −0.67; 10 RCTs; very low certainty), cough (MD −1.02 days, 95%CI −1.23 to −0.81; 9 RCTs; moderate certainty), phlegm (MD −1.46 days, 95%CI −2.84 to −0.08; 6 RCTs; very low certainty), pulmonary crepitations (MD −1.61 days, 95%CI −2.64 to −0.59; 8 RCTs; low certainty), shortness of breath (MD −2.80 days, 95%CI −2.88 to −2.72; 2 RCTs; low certainty) and chest pain (MD −2.85 days, 95%CI −3.01 to −2.69; 1 RCT; low certainty). There was no significant difference in pathogen clearance (1 RCT). No serious adverse events were reported, but 2.60% (5/192) patients reported nausea in the SFJD groups, 1.04% (2/192) participants in routine group, and no significant difference was identified. Conclusions: Current evidence suggests that adding SFJD may shorten the duration of symptom relief in community-acquired pneumonia for 1–2 days. The adverse events were minor and controllable, and no serious adverse events were reported. Well-reported trials and potential of reducing antibiotics were expected in the future studies. |
format | Online Article Text |
id | pubmed-9289368 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92893682022-07-19 Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials Zhang, Xiao-Wen Xia, Ru-Yu Gao, Jia-Qi Liu, Jin-Jun Xu, De-Hao Li, Xun Hu, Xiao-Yang Willcox, Merlin Moore, Michael Dai, Meng-Yuan Trill, Jeanne Fei, Yu-Tong Liu, Jian-Ping Front Pharmacol Pharmacology Background: Shufeng Jiedu (SFJD) capsules can be used as adjunctive treatment for patients with community-acquired pneumonia, but the effectiveness and safety of SFJD are not clear. This review aims to evaluate the effectiveness and safety of SFJD based on randomized controlled trials (RCTs). Methods: A systematic review was conducted by searching PubMed, Embase, Scopus, Web of Science, CENTRAL, CNKI, VIP, CBM, Wanfang and trial registry platforms from their inception to March 2022. Two reviewers screened studies, extracted the data and assessed risk of bias independently. The data were pooled for meta-analysis or presented narratively. Results: Seventeen RCTs involving 1840 participants were included. All trials compared SFJD plus antibiotics to antibiotics, or combined with symptomatic treatment in both groups. The overall certainty of evidence was assessed as moderate to very low certainty. Compared with routine treatment (antibiotics alone or antibiotics plus symptomatic treatment), SFJD plus routine treatment showed beneficial effects in resolution of fever (MD −1.20 days, 95%CI −1.73 to −0.67; 10 RCTs; very low certainty), cough (MD −1.02 days, 95%CI −1.23 to −0.81; 9 RCTs; moderate certainty), phlegm (MD −1.46 days, 95%CI −2.84 to −0.08; 6 RCTs; very low certainty), pulmonary crepitations (MD −1.61 days, 95%CI −2.64 to −0.59; 8 RCTs; low certainty), shortness of breath (MD −2.80 days, 95%CI −2.88 to −2.72; 2 RCTs; low certainty) and chest pain (MD −2.85 days, 95%CI −3.01 to −2.69; 1 RCT; low certainty). There was no significant difference in pathogen clearance (1 RCT). No serious adverse events were reported, but 2.60% (5/192) patients reported nausea in the SFJD groups, 1.04% (2/192) participants in routine group, and no significant difference was identified. Conclusions: Current evidence suggests that adding SFJD may shorten the duration of symptom relief in community-acquired pneumonia for 1–2 days. The adverse events were minor and controllable, and no serious adverse events were reported. Well-reported trials and potential of reducing antibiotics were expected in the future studies. Frontiers Media S.A. 2022-07-04 /pmc/articles/PMC9289368/ /pubmed/35860018 http://dx.doi.org/10.3389/fphar.2022.923395 Text en Copyright © 2022 Zhang, Xia, Gao, Liu, Xu, Li, Hu, Willcox, Moore, Dai, Trill, Fei and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Zhang, Xiao-Wen Xia, Ru-Yu Gao, Jia-Qi Liu, Jin-Jun Xu, De-Hao Li, Xun Hu, Xiao-Yang Willcox, Merlin Moore, Michael Dai, Meng-Yuan Trill, Jeanne Fei, Yu-Tong Liu, Jian-Ping Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
title | Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
title_full | Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
title_fullStr | Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
title_full_unstemmed | Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
title_short | Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
title_sort | chinese patent medicine shufeng jiedu capsules as an adjuvant therapy for community-acquired pneumonia: a systematic review and meta-analysis of randomized clinical trials |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289368/ https://www.ncbi.nlm.nih.gov/pubmed/35860018 http://dx.doi.org/10.3389/fphar.2022.923395 |
work_keys_str_mv | AT zhangxiaowen chinesepatentmedicineshufengjieducapsulesasanadjuvanttherapyforcommunityacquiredpneumoniaasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT xiaruyu chinesepatentmedicineshufengjieducapsulesasanadjuvanttherapyforcommunityacquiredpneumoniaasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT gaojiaqi chinesepatentmedicineshufengjieducapsulesasanadjuvanttherapyforcommunityacquiredpneumoniaasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT liujinjun chinesepatentmedicineshufengjieducapsulesasanadjuvanttherapyforcommunityacquiredpneumoniaasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT xudehao chinesepatentmedicineshufengjieducapsulesasanadjuvanttherapyforcommunityacquiredpneumoniaasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT lixun chinesepatentmedicineshufengjieducapsulesasanadjuvanttherapyforcommunityacquiredpneumoniaasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT huxiaoyang chinesepatentmedicineshufengjieducapsulesasanadjuvanttherapyforcommunityacquiredpneumoniaasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT willcoxmerlin chinesepatentmedicineshufengjieducapsulesasanadjuvanttherapyforcommunityacquiredpneumoniaasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT mooremichael chinesepatentmedicineshufengjieducapsulesasanadjuvanttherapyforcommunityacquiredpneumoniaasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT daimengyuan chinesepatentmedicineshufengjieducapsulesasanadjuvanttherapyforcommunityacquiredpneumoniaasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT trilljeanne chinesepatentmedicineshufengjieducapsulesasanadjuvanttherapyforcommunityacquiredpneumoniaasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT feiyutong chinesepatentmedicineshufengjieducapsulesasanadjuvanttherapyforcommunityacquiredpneumoniaasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT liujianping chinesepatentmedicineshufengjieducapsulesasanadjuvanttherapyforcommunityacquiredpneumoniaasystematicreviewandmetaanalysisofrandomizedclinicaltrials |